# Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits

Study · id `cardio:ct-nct06115070` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06115070](<https://clinicaltrials.gov/study/NCT06115070>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06115070

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 390 participants.

## Technical summary

Registry record NCT06115070. Randomized; single masking; primary purpose treatment. Start 2025-03-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 390 participants (planned count; ClinicalTrials.gov record NCT06115070, source copy `cardio:ctgov-nct06115070-2025-03-06`, retrieved 2026-10-26)
- Planned start: 2025-03-01 (anticipated) (ClinicalTrials.gov record NCT06115070, source copy `cardio:ctgov-nct06115070-2025-03-06`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT06115070, source copy `cardio:ctgov-nct06115070-2025-03-06`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06115070, source copy `cardio:ctgov-nct06115070-2025-03-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06115070, source copy `cardio:ctgov-nct06115070-2025-03-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06115070-2025-03-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits
- Acronym: ALLOW
- Condition: Thrombosis
- Condition: Acute Ischemic Stroke (AIS)
- Intervention (Drug): Intravenous thrombolysis (alteplase and other guideline-recommended thrombolytic agents)
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 745e807fc77be433cc071ad46d58098be8c3be91963ab085f92cd2d22ab2ae0a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
